TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23355041

Group type: EXPERIMENTAL
Intervention: Combination therapy of gemcitabine and S‐1 (gemcitabine 1,000 mg/m(2) on days 1 and 15 and S‐1 40 mg/m(2) b.i.d. on days 1‐14, repeated every 4 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (gemcitabine 1,000 mg/m(2) on days 1, 8, and 15, repeated every 4 weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination therapy of gemcitabine and S‐1
Number of subjects: 62

Group type: COMPARATOR
Intervention: Gemcitabine monotherapy
Number of subjects: 62
Study: 21188597

Group type: EXPERIMENTAL
Intervention: Intranasal steroid (INS) therapy (mometasone furoate)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Radiofrequency turbinoplasty (RFT)
Number of subjects: 55
Study: 19265046

Group type: EXPERIMENTAL
Intervention: Factor Seven for Acute Hemorrhagic Stroke (FAST) intervention
Number of subjects: 657

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 657
Study: 17855670

Group type: EXPERIMENTAL
Intervention: Idraparinux (2.5 mg once weekly)
Number of subjects: 5119

Group type: COMPARATOR
Intervention: Standard therapy (heparin followed by vitamin K antagonist)
Number of subjects: 5119
Study: 16574046

Group type: EXPERIMENTAL
Intervention: Increasing the certainty of apprehension for DUIC
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Doubling the severity of penalties for DUIC
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Providing factual information about the accident risk associated with DUIC
Number of subjects: 320
Study: 12728284

Group type: COMPARATOR
Intervention: Etanercept (TNF antagonist)
Number of subjects: 265
Study: 10417520

Group type: EXPERIMENTAL
Intervention: 1% capsaicin applied for 60 min
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topical capsaicin applied for 24 h
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo applied for 24 h
Number of subjects: 22
Study: 8936891

Group type: EXPERIMENTAL
Intervention: School-based, nurse-administered relaxation training
Number of subjects: 26

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 26
Study: 1660824

Group type: EXPERIMENTAL
Intervention: Azithromycin (1.5 g in five or six doses over 5 days)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Erythromycin (14 or 20 g in 28 or 40 doses over 7 or 10 days)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Amoxycillin (10.5 g in 21 doses over 7 days)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 2
Study: 7076116

Group type: COMPARATOR
Intervention: 10 mg per kg per day of ursodeoxycholic acid (UDCA) for 45 to 60 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of 5 mg per kg per day of chenodeoxycholic acid (CDCA) and 5 mg per kg per day of ursodeoxycholic acid (UDCA) for 45 to 60 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: 10 mg per kg per day of chenodeoxycholic acid (CDCA) for 45 to 60 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of CDCA and UDCA
Number of subjects: 18

Group type: COMPARATOR
Intervention: 10 mg per kg per day of chenodeoxycholic acid (CDCA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 10 mg per kg per day of ursodeoxycholic acid (UDCA)
Number of subjects: 18
Study: 31981648

Group type: EXPERIMENTAL
Intervention: MCCG-2
Number of subjects: 80

Group type: COMPARATOR
Intervention: MCCG-1
Number of subjects: 80
Study: 28847198

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU)
Number of subjects: 40
Study: 28178589

Group type: EXPERIMENTAL
Intervention: Ethanol presence in blood and urine during hangover state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current consensus on cognitive testing timing
Number of subjects: 0
Study: 26411467

Group type: EXPERIMENTAL
Intervention: Equivalence-based instruction (EBI)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Criterion-control group (random relations)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Trial-control group (same number of trials as EBI)
Number of subjects: 61
Study: 23263729

Group type: EXPERIMENTAL
Intervention: Carbon-ion therapy with compensating boli designed for PTV1 and PTV2 at peak-exhalation phase
Number of subjects: 20
Study: 21269348

Group type: COMPARATOR
Intervention: Melanocytes suspended in normal saline
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Melanocytes suspended in patients' own serum
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study: 18179662

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Other second-generation antipsychotics (SGAs)
Number of subjects: 100
Study: 16876044

Group type: EXPERIMENTAL
Intervention: Absorbable gelatin sponge
Number of subjects: 104

Group type: COMPARATOR
Intervention: No absorbable gelatin sponge (control)
Number of subjects: 104
Study: 12615625

Group type: EXPERIMENTAL
Intervention: n-3 lipid emulsion rich in eicosapentaenoic acid and docosahexaenoic acid
Number of subjects: 21

Group type: COMPARATOR
Intervention: conventional (n-6) lipid emulsion (index fatty acid: arachidonic acid)
Number of subjects: 21
Study: 11258587

Group type: EXPERIMENTAL
Intervention: 6% oxygen enrichment of room air at simulated 5,000 m altitude
Number of subjects: 24

Group type: COMPARATOR
Intervention: Simulated breathing air at 5,000 m
Number of subjects: 24
Study: 9499495

Group type: EXPERIMENTAL
Intervention: c7E3 (ReoPro)
Number of subjects: 520
Study: 8239567

Group type: EXPERIMENTAL
Intervention: Thiamine 5 gm p.o. and scopolamine 0.007 mg/kg IM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactose PO and scopolamine 0.007 mg/kg IM
Number of subjects: 0
Study: 4083104

Group type: COMPARATOR
Intervention: 0 puffs of tobacco smoke
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 2 puffs of tobacco smoke
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 4 puffs of tobacco smoke
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 8 puffs of tobacco smoke
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 12 puffs of tobacco smoke
Number of subjects: 5
Study: 29915617

Group type: EXPERIMENTAL
Intervention: Systematic medication review with collegial mentoring
Number of subjects: 295

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 295
Study: 26894924

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg/day
Number of subjects: 4545

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day
Number of subjects: 4545

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 4545

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4545

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (all doses)
Number of subjects: 4545
Study: 24935613

Group type: EXPERIMENTAL
Intervention: Wii Active (Wii‐Acti)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wii Family Trainer (Wii‐Train)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Wii Fit Plus (Wii‐Fit)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 6-min walk test (6MWT)
Number of subjects: 24
Study: 23538521

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM197 vaccine administered at 2 and 4 months of age
Number of subjects: 216

Group type: COMPARATOR
Intervention: Maternal antibodies
Number of subjects: 216
Study: 20560366

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 32
Study: 18390022

Group type: EXPERIMENTAL
Intervention: Special recruitment efforts for blacks and Hispanics at specific centers.
Number of subjects: 155000

Group type: EXPERIMENTAL
Intervention: Recruitment efforts at two centers for blacks, including one with a major special recruitment effort.
Number of subjects: 155000

Group type: EXPERIMENTAL
Intervention: Recruitment efforts at a center with a special Hispanic recruitment effort.
Number of subjects: 155000

Group type: COMPARATOR
Intervention: Comparison of minority enrollment to age-eligible population.
Number of subjects: 155000
Study: 16810506

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 169

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Aripiprazole and Olanzapine
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Continuous Performance Test-Identical Pairs
Number of subjects: 169
Study: 14587303

Group type: EXPERIMENTAL
Intervention: Val 160 mg
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: Val 160 mg/HCTZ 12.5 mg
Number of subjects: 2002

Group type: EXPERIMENTAL
Intervention: Val 160 mg/HCTZ 25 mg
Number of subjects: 2002
Study: 12356001

Group type: EXPERIMENTAL
Intervention: Indapamide SR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 0
Study: 10491452

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 or 1600 microg daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 8578093

Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed commercial amino acids (Control)
Number of subjects: 0
Study: 1790547

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg orally every 12 hours for 10 days
Number of subjects: 335

Group type: COMPARATOR
Intervention: Cephalexin 500 mg orally every six hours for 10 days
Number of subjects: 335
Study: 7110300

Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 30477950

Group type: EXPERIMENTAL
Intervention: Mesorectal excision with lateral lymph node dissection (LLND)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Mesorectal excision alone
Number of subjects: 328
Study: 29048966

Group type: EXPERIMENTAL
Intervention: Weekly SMS message group
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Weekly SMS message with response option group
Number of subjects: 332

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 332
Study: 27342744

Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxegol (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relief of OIC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25109720

Group type: EXPERIMENTAL
Intervention: Gamma oryzanol supplementation (600 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 30
Study: 23045591

Group type: EXPERIMENTAL
Intervention: Mammostrat test (immunohistochemical multigene assay)
Number of subjects: 4598

Group type: EXPERIMENTAL
Intervention: Mammostrat test
Number of subjects: 4598

Group type: COMPARATOR
Intervention: Tamoxifen and exemestane treatment
Number of subjects: 4598
Study: 19581222

Group type: EXPERIMENTAL
Intervention: Intimate-partner dyads
Number of subjects: 205

Group type: COMPARATOR
Intervention: Family-member dyads
Number of subjects: 205

Group type: COMPARATOR
Intervention: Nonfamily-member dyads
Number of subjects: 205
Study: 17468085

Group type: EXPERIMENTAL
Intervention: MCT oil-supplemented diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: non-MCT oil diet
Number of subjects: 17
Study: 16055868

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg q.d.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg b.i.d.
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combination therapy (Tiotropium + Formoterol) q.d.
Number of subjects: 71
Study: 12421725

Group type: EXPERIMENTAL
Intervention: Post-genomic science and high throughput technologies
Number of subjects: 29000

Group type: COMPARATOR
Intervention: Clinicopathological prognostic markers
Number of subjects: 29000
Study: 9545143

Group type: EXPERIMENTAL
Intervention: Statins (HMG-coenzyme A reductase inhibitors)
Number of subjects: 0
Study: 8006330

Group type: EXPERIMENTAL
Intervention: 30 g i.v. ARG (group A)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 10 g i.v. ARG (group B)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 8 g oral ARG (group D)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 5 g i.v. ARG (group C)
Number of subjects: 27
Study: 2681560

Group type: EXPERIMENTAL
Intervention: Aztreonam + Clindamycin
Number of subjects: 454

Group type: COMPARATOR
Intervention: Gentamicin + Clindamycin
Number of subjects: 454
Study: 1101909

Group type: EXPERIMENTAL
Intervention: 59iron‐sulphate‐DL‐serin combination (group B)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 59iron‐sulphate (group A)
Number of subjects: 19
Study: 29486763

Group type: EXPERIMENTAL
Intervention: Counselling on diet and physical activity by municipal health-care staff
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Intervention group (counselling)
Number of subjects: 185
Study: 26531235

Group type: EXPERIMENTAL
Intervention: Tension-free primary closure
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Limberg flap
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Karydakis technique
Number of subjects: 150
Study: 25515973

Group type: EXPERIMENTAL
Intervention: Obstetric gel
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no gel)
Number of subjects: 47
Study: 23668772

Group type: EXPERIMENTAL
Intervention: Physician education
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Both physician education and patient education
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control (no education)
Number of subjects: 468
Study: 20516313

Group type: EXPERIMENTAL
Intervention: Active motion therapy (place-and-hold)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Passive motion therapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Active motion therapy
Number of subjects: 103
Study: 18259824

Group type: EXPERIMENTAL
Intervention: High dominance and low caring
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: High dominance and high caring
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Low dominance and low caring
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Low dominance and high caring
Number of subjects: 167

Group type: COMPARATOR
Intervention: High dominance
Number of subjects: 167

Group type: COMPARATOR
Intervention: High caring
Number of subjects: 167
Study: 16364936

Group type: EXPERIMENTAL
Intervention: Expedited cataract surgery (approximately 4 weeks wait)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Routine cataract surgery (12 months wait)
Number of subjects: 239
Study: 14627528

Group type: EXPERIMENTAL
Intervention: Aprotinin treatment
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 38
Study: 11194530

Group type: EXPERIMENTAL
Intervention: Lecithin (4 capsules BID; PhosChol 900) providing approximately 1.1 g of choline daily (2.2 g total)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10437237

Group type: EXPERIMENTAL
Intervention: Powder composed of Radix Ginseng, Radix Notoginseng and Succinum
Number of subjects: 116

Group type: COMPARATOR
Intervention: Fufang Danshen Tablet
Number of subjects: 116
Study: 8336303

Group type: EXPERIMENTAL
Intervention: Range of motion exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Range of motion plus balanced resistive exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home hand exercise (exercise groups combined)
Number of subjects: 0
Study: 3534568

Group type: EXPERIMENTAL
Intervention: 14-valent pneumococcal capsular polysaccharide vaccine
Number of subjects: 2295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2295
Study: 2681554

Group type: EXPERIMENTAL
Intervention: Ifosfamide plus doxorubicin (doxorubicin 60 mg/m2 by continuous push, ifosfamide 5.0 g/m2 by continuous infusion over 24 hours with mesna 7.5 g/m2 over 36 hours, courses every 3 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ifosfamide plus doxorubicin
Number of subjects: 42
Study: 31638936

Group type: EXPERIMENTAL
Intervention: Short message service (SMS) to improve medication adherence
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Short message service (SMS)
Number of subjects: 422
Study: 29050005

Group type: EXPERIMENTAL
Intervention: Low-salt diet (3.0g/day of NaCl)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High-salt diet (18.0g/day of NaCl)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Baseline diet
Number of subjects: 38
Study: 26467984

Group type: EXPERIMENTAL
Intervention: 1 mg/kg tramadol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2-mL saline (control)
Number of subjects: 60
Study: 23507709

Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin (20 mg/day)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Low-dose rosuvastatin (2.5 mg/day)
Number of subjects: 232
Study: 22409115

Group type: EXPERIMENTAL
Intervention: One-to-one teaching with rehearsal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 18637133

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 0
Study: 16506862

Group type: EXPERIMENTAL
Intervention: GXT(3‐min)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GXT(5‐min)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 30‐minute TT
Number of subjects: 11
Study: 12671544

Group type: EXPERIMENTAL
Intervention: Strengthened STD services including periodic screening and treatment for gonorrhea, chlamydial infection, trichomoniasis, bacterial vaginosis (BV), and syphilis; counseling; and supply of condoms
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Consistent condom use (CCU) during follow-up
Number of subjects: 917
Study: 10480041

Group type: EXPERIMENTAL
Intervention: Guided self-hypnotic relaxation using a standardized protocol and script
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Guided self-hypnotic relaxation
Number of subjects: 56
Study: 7489421

Group type: EXPERIMENTAL
Intervention: ondansetron 0.15 mg.kg‐1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: metoclopramide 0.25 mg.kg‐1
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 45
Study: 1880256

Group type: COMPARATOR
Intervention: Photopatch test with a standard tray of 32 substances, irradiated with 10 joules/cm2 UVA after 24 hours.
Number of subjects: 1129
Study: 6809322

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard nutrition
Number of subjects: 36

Group type: COMPARATOR
Intervention: TPN and Standard nutrition (comparison)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TPN and Standard nutrition (subgroup analysis)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TPN and Standard nutrition (cycle-by-cycle analysis)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TPN and Standard nutrition (laboratory measures)
Number of subjects: 36
Study: 30819084

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment with clozapine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lipid-lowering agents
Number of subjects: 14
Study: 28451013

Group type: EXPERIMENTAL
Intervention: Group exercise 2X/week
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group exercise 3X/week
Number of subjects: 100
Study: 26620120

Group type: EXPERIMENTAL
Intervention: One-time sigmoidoscopy screening
Number of subjects: 98792

Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 98792
Study: 23248197

Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg q.d. for moderate renal insufficiency and 25 mg q.d. for severe renal insufficiency)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Glipizide (2.5 mg q.d., adjusted based on glycemic control to a 10 mg twice a day maximum dose)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 426

Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 426
Study: 21641106

Group type: EXPERIMENTAL
Intervention: Decision protocol for type of delivery of breech presentations
Number of subjects: 1133
Study: 18295467

Group type: EXPERIMENTAL
Intervention: Zinc picolinate supplementation (22 mg daily for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy non-smokers)
Number of subjects: 30
Study: 17201084

Group type: EXPERIMENTAL
Intervention: Roller pump
Number of subjects: 14

Group type: COMPARATOR
Intervention: Centrifugal pump
Number of subjects: 14
Study: 12490772

Group type: EXPERIMENTAL
Intervention: Pharmacological intervention (venlafaxine and paroxetine)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Improvement in symptoms
Number of subjects: 150

Group type: COMPARATOR
Intervention: Baseline self-directedness score
Number of subjects: 150
Study: 10917578

Group type: EXPERIMENTAL
Intervention: Cyclo 3 Fort
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hydroxyethyl rutoside (rutoside)
Number of subjects: 80
Study: 8807761

Group type: EXPERIMENTAL
Intervention: Intensive antibiotic therapy plus early ultrasound-guided vaginal drainage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intensive antibiotic therapy alone
Number of subjects: 40
Study: 1461786

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (40 mg/Kg/dose for 4 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous amoxicillin (40 mg/Kg/dose for 4 days)
Number of subjects: 32
Study: 6394131

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1 gm)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 31464588

Group type: EXPERIMENTAL
Intervention: Group-based psychosocial program including cognitive stimulation, expansion of social support networks, and cognitive behaviour strategies.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 30497484

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) 25g
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Casein protein (CAS) 25g
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Maltodextrin (MAL) 25g
Number of subjects: 11

Group type: COMPARATOR
Intervention: Non-caloric control (CON)
Number of subjects: 11